#United States #Camarillo #PBS Biotech #Martin Simonetti #bioreactor systems

PBS Biotech Welcomes Martin Simonetti as New CEO

PBS Biotech, known for pioneering single-use bioreactor systems, has announced the appointment of Martin Simonetti as its new Chief Executive Officer as of October 27th, 2025. With a rich industry background spanning over four decades, Simonetti brings a wealth of experience in biotechnology leadership and innovation.

Leadership Evolution at PBS Biotech

In this strategic shift, PBS founder Dr. Brian Lee will transition into the role of Chief Technology Officer, focusing on technology strategy and product innovation while still serving as Chairman of the Board. This leadership change is viewed as a critical step to navigating the company through its next phase of growth within the thriving sector of bioprocess development and cell therapy.

Dr. Brian Lee expressed his enthusiasm, stating, "I'm thrilled to welcome Marty as CEO of PBS Biotech. He brings the strategic insight and operational leadership needed to guide PBS through its next phase of growth. Marty is the right leader to drive our expansion and position PBS as the go-to partner for cell and gene therapy companies transforming patient treatment."

Simonetti’s Extensive Experience in Biotech

Before joining PBS Biotech, Simonetti was a key player at VLST Corporation, where he served as President and CEO. His background also includes significant roles at Dendreon Corporation, where he was responsible for financial oversight and corporate strategy. As a former Vice President at Amgen, he played a vital role in operations and finance within the biotechnology sector, ensuring the scaling of innovative solutions that meet market demands.

Throughout his career, Simonetti has demonstrated a talent for driving growth and steering transformation in emerging biotech ventures and global life sciences organizations. His deep understanding of the industry's dynamics positions him well to lead PBS Biotech in expanding its footprint.

PBS Biotech’s Vision for the Future

In his own words, Simonetti remarked, "PBS Biotech is a proven innovator in bioreactor technology as well as biomanufacturing processes and is poised to expand its leadership in the rapidly growing cell therapy market. Having served on the PBS Advisory Board for nearly a decade, I'm honored to step into this role and work with Brian and the team to scale our impact as demand for advanced bioprocessing solutions accelerates. Together, we'll help our customers translate breakthrough science into real-world treatments that improve patients' lives."

The company is also backed by prominent investors, including Avego, a multi-strategy healthcare-focused investment firm, and BroadOak, which specializes in life sciences funding. These partnerships are indicative of PBS Biotech's robust positioning in the market.

About PBS Biotech

PBS Biotech is dedicated to providing cutting-edge single-use bioreactor systems and process development services. Their proprietary Vertical-Wheel® technology promises scalable and low-shear mixing necessary for various cell therapy applications. The company's ultimate goal is to establish a global standard for manufacturing allogeneic cell-based therapies. For more details, visit pbsbiotech.com.

As PBS Biotech embarks on this new chapter under Simonetti's leadership, the industry will be watching closely to see how they continue to innovate and lead in the ever-evolving field of biotechnology.